The FDA has granted CooperVision approval for its new Biofinity toric multifocal contact lenses. The product combines the optical designs of CooperVision’s Biofinity toric—the most prescribed toric lens on the market1—and Biofinity multifocal to provide patients with astigmatism and presbyopia vision correction. The company plans to make the lenses available to US eye care professionals later this year, followed by other markets.
“Biofinity toric multifocal extends the reliable performance of our Biofinity toric lenses to presbyopic patients,” Michele Andrews, OD, Senior Director, Professional and Academic Affairs, North America, CooperVision, said in a company news release. “US eye care professionals will soon have an easy-to-fit, familiar lens design they can count on to keep current toric wearers satisfied in contact lenses for longer, and provide new astigmatic wearers an alternative to reading glasses. It’s a win-win for practitioners and their patients.”
Lens parameters and other details regarding Biofinity toric multifocal will be made public in the coming months.
1 US industry data on file